279 related articles for article (PubMed ID: 8541533)
1. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
Cazzola M; Messinger D; Battistel V; Bron D; Cimino R; Enller-Ziegler L; Essers U; Greil R; Grossi A; Jäger G; LeMevel A; Najman A; Silingardi V; Spriano M; van Hoof A; Ehmer B
Blood; 1995 Dec; 86(12):4446-53. PubMed ID: 8541533
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.
Osterborg A; Boogaerts MA; Cimino R; Essers U; Holowiecki J; Juliusson G; Jäger G; Najman A; Peest D
Blood; 1996 Apr; 87(7):2675-82. PubMed ID: 8639883
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
Mittelman M; Zeidman A; Fradin Z; Magazanik A; Lewinski UH; Cohen A
Acta Haematol; 1997; 98(4):204-10. PubMed ID: 9401498
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.
Osterborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D;
J Clin Oncol; 2002 May; 20(10):2486-94. PubMed ID: 12011126
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
Cazzola M; Beguin Y; Kloczko J; Spicka I; Coiffier B
Br J Haematol; 2003 Aug; 122(3):386-93. PubMed ID: 12877665
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation.
Van Biesen W; Vanholder R; Veys N; Verbeke F; Lameire N
Transplantation; 2005 Feb; 79(3):367-8. PubMed ID: 15699772
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
Cazzola M; Ponchio L; Beguin Y; Rosti V; Bergamaschi G; Liberato NL; Fregoni V; Nalli G; Barosi G; Ascari E
Blood; 1992 Jan; 79(1):29-37. PubMed ID: 1728318
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
9. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
[TBL] [Abstract][Full Text] [Related]
12. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.
Yang S; Jun M; Hong-Li Z; Jian-Min W; Chun W; Lu-Gui Q; Yong-Qiang Z; Jun Z; Jian H; Zhi-Xiang S
Int J Hematol; 2008 Sep; 88(2):139-144. PubMed ID: 18629603
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
14. A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy.
Dmoszynska A; Kloczko J; Rokicka M; Hellmann A; Spicka I; Eid JE
Haematologica; 2007 Apr; 92(4):493-501. PubMed ID: 17488660
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma.
San Miguel JF; García-Sanz R
Med Oncol; 1998 Aug; 15 Suppl 1():S29-34. PubMed ID: 9785334
[TBL] [Abstract][Full Text] [Related]
18. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients.
Martino M; Oliva E; Console G; Stelitano C; Fujo M; Messina G; Irrera G; Pucci G; Mandaglio R; Callea V; Nobile F; Iacopino P; Morabito F
Support Care Cancer; 2005 Mar; 13(3):182-7. PubMed ID: 15480819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.
Oster W; Herrmann F; Gamm H; Zeile G; Lindemann A; Müller G; Brune T; Kraemer HP; Mertelsmann R
J Clin Oncol; 1990 Jun; 8(6):956-62. PubMed ID: 2189957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
